Wedbush analyst David Nierengarten reiterated an Outperform rating on bluebird bio (NASDAQ: BLUE) following today's ASH abstract update but cut ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA Trader Talk

bluebird bio (BLUE) Price Target Reduced to $149 at BofA/Merrill LynchNovember 6, 2015 7:34 AM Too Earlier to Write Off bluebird bio's (BLUE) LentiGlobin in Subset - CowenNovember 5, 2015 3:44 PM bluebird bio (BLUE) LentiGlobin is Here To Stay, Roth Capital Says; PT Cut to $165November 5, 2015 1:27 PM bluebird bio (BLUE) LentiGlobin 'Does Work', Maxim Group SaysNovember 5, 2015 1:06 PM 'Not Time to Hit Panic Button' on bluebird bio (BLUE), Oppenheimer SaysNovember 5, 2015 12:23 PM bluebird bio (BLUE) Post-ASH Abstract Sell-Off an 'Overreaction', Oppenheimer SaysNovember 5, 2015 11:00 AM bluebird bio (BLUE) Plunges 14% in Early Trade Following ASH UpdateNovember 5, 2015 8:20 AM